“Placebo-Controlled Trial of Pharmaceutical Optimized Hydralazine 25mg (F-6) in Patients with Essential Hypertension”, mfm, vol. 30, no. 5, May 2024, Accessed: Nov. 16, 2025. [Online]. Available: https://medicalforummonthly.com/index.php/mfm/article/view/3666